Gillian D Sanders

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10577095/publications.pdf

Version: 2024-02-01

80 papers	8,005 citations	101543 36 h-index	71685 76 g-index
82 all docs	82 docs citations	82 times ranked	10505 citing authors

#	Article	IF	Citations
1	Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses. JAMA - Journal of the American Medical Association, 2016, 316, 1093.	7.4	2,149
2	Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy. New England Journal of Medicine, 2005, 352, 570-585.	27.0	552
3	Cost-Effectiveness of Implantable Cardioverterâ€“Defibrillators. New England Journal of Medicine, 2005, 353, 1471-1480.	27.0	492
4	Benefits and Harms of Breast Cancer Screening. JAMA - Journal of the American Medical Association, 2015, 314, 1615.	7.4	473
5	Evaluating Human Papillomavirus Vaccination Programs. Emerging Infectious Diseases, 2004, 10, 1915-1923.	4.3	327
6	Systematic Review of the Incidence of Sudden Cardiac Death in the United States. Journal of the American College of Cardiology, 2011, 57, 794-801.	2.8	287
7	Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial Cancers: A Systematic Review. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1931-1943.	2.5	287
8	Cost Effectiveness of a Potential Vaccine forHuman papillomavirus. Emerging Infectious Diseases, 2003, 9, 37-48.	4.3	273
9	Oral Contraceptives and Risk of Ovarian Cancer and Breast Cancer Among High-Risk Women: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2013, 31, 4188-4198.	1.6	221
10	Nonâ€“Evidence-Based ICD Implantations in the United States. JAMA - Journal of the American Medical Association, 2011, 305, 43.	7.4	207
11	Oral Contraceptive Pills as Primary Prevention for Ovarian Cancer. Obstetrics and Gynecology, 2013, 122, 139-147.	2.4	202
12	Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. Thrombosis and Haemostasis, 2018, 118, 2171-2187.	3.4	160
13	Risk of Acute Thromboembolic Events With Oral Contraceptive Use. Obstetrics and Gynecology, 2013, 122, 380-389.	2.4	127
14	Cost-Effectiveness Analysis 2.0. New England Journal of Medicine, 2017, 376, 203-205.	27.0	100
15	Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis.. European Journal of Endocrinology, 2008, 158, 841-851.	3.7	99
16	Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death in CKD: A Meta-analysis of Patient-Level Data From 3 Randomized Trials. American Journal of Kidney Diseases, 2014, 64, 32-39.	1.9	89
17	Costs and Cost-effectiveness of Four Treatment Regimens for Latent Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 1055-1060.	5.6	86
18	Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy. JAMA Cardiology, 2017, 2, 685.	6.1	82

#	Article	IF	Citations
19	Improving HIV Screening and Receipt of Results by Nurse-Initiated Streamlined Counseling and Rapid Testing. Journal of General Internal Medicine, 2008, 23, 800-807.	2.6	78
20	Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. American Heart Journal, 2002, 144, 440-448.	2.7	77
21	Outcomes of Implantable Cardioverter-Defibrillator Use in Patients With Comorbidities. JACC: Heart Failure, 2014, 2, 623-629.	4.1	72
22	Overview of Cost-effectiveness Analysis. JAMA - Journal of the American Medical Association, 2019, 321, 1400.	7.4	71
23	Potential Cost-Effectiveness of Prophylactic Use of the Implantable Cardioverter Defibrillator or Amiodarone after Myocardial Infarction. Annals of Internal Medicine, 2001, 135, 870.	3.9	70
24	Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age. Annals of Internal Medicine, 2008, 148, 889.	3.9	69
25	Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. Aids, 2006, 20, 2207-2215.	2.2	60
26	Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: Randomized trial evidence through 2004. American Heart Journal, 2005, 149, 1020-1034.	2.7	59
27	Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study. Nephrology Dialysis Transplantation, 2015, 30, 829-835.	0.7	59
28	Future Directions for Cost-effectiveness Analyses in Health and Medicine. Medical Decision Making, 2018, 38, 767-777.	2.4	58
29	Preventing tomorrow's sudden cardiac death today. American Heart Journal, 2008, 156, 613-622.	2.7	46
30	Survival After Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients With Chronic Kidney Disease. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 793-799.	4.8	45
31	Cost-Effectiveness of Strategies to Improve HIV Testing and Receipt of Results: Economic Analysis of a Randomized Controlled Trial. Journal of General Internal Medicine, 2010, 25, 556-563.	2.6	43
32	Evaluating Cough Assessment Tools. Chest, 2013, 144, 1819-1826.	0.8	43
33	Cost-effectiveness as an outcome in randomized clinical trials. Clinical Trials, 2006, 3, 543-551.	1.6	42
34	Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?. Gynecologic Oncology, 2008, 111, 179-187.	1.4	38
35	Prevalence of HIV Infection Among Inpatients and Outpatients in Department of Veterans Affairs Health Care Systems: Implications for Screening Programs for HIV. American Journal of Public Health, 2007, 97, 2173-2178.	2.7	37
36	Efficacy and Tolerability of Treatments for Chronic Cough. Chest, 2013, 144, 1827-1838.	0.8	36

#	Article	IF	Citations
37	Cost-effectiveness of implantable cardioverter defibrillators in patients â‰¥65 years of age. American Heart Journal, 2010, 160, 122-131.	2.7	35
38	Association Between Prophylactic Implantable Cardioverter-Defibrillators and Survival in Patients With Left Ventricular Ejection Fraction Between 30% and 35%. JAMA - Journal of the American Medical Association, 2014, 311, 2209.	7.4	35
39	Prioritization of Research Addressing Management Strategies for Ductal Carcinoma In Situ. Annals of Internal Medicine, 2014, 160, 484.	3.9	35
40	New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials. American Heart Journal, 2017, 191, 21-29.	2.7	35
41	Evidence-Based Medicine And Policy: The Case Of The Implantable Cardioverter Defibrillator. Health Affairs, 2005, 24, 42-51.	5.2	33
42	Evidence-based practice for mere mortals. Journal of General Internal Medicine, 2002, 17, 302-308.	2.6	30
43	Development of an ovarian cancer screening decision model that incorporates disease heterogeneity. Cancer, 2011, 117, 545-553.	4.1	30
44	Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. JACC: Heart Failure, 2015, 3, 159-167.	4.1	30
45	Identifying Research Needs for Improving Health Care. Annals of Internal Medicine, 2012, 157, 439.	3.9	29
46	Prioritization of Patient-Centered Comparative Effectiveness Research for Osteoarthritis. Annals of Internal Medicine, 2014, 160, 836.	3.9	29
47	Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. Circulation: Heart Failure, 2016, 9, e002630.	3.9	28
48	Distributed Decision Support Using a Web-based Interface. Medical Decision Making, 1999, 19, 157-166.	2.4	27
49	Design and Pilot Evaluation of a System to Develop Computer-based Site-specific Practice Guidelines from Decision Models. Medical Decision Making, 2000, 20, 145-159.	2.4	25
50	Implantable cardioverterâ€defibrillators in heart failure patients with reduced ejection fraction and diabetes. European Journal of Heart Failure, 2018, 20, 1031-1038.	7.1	24
51	HIV Testing of At Risk Patients in a Large Integrated Health Care System. Journal of General Internal Medicine, 2007, 22, 315-320.	2.6	22
52	Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapies. American Heart Journal, 2010, 160, 605-618.e1.	2.7	21
53	Potential Economic Viability of Two Proposed Rifapentine-Based Regimens for Treatment of Latent Tuberculosis Infection. PLoS ONE, 2011, 6, e22276.	2.5	20
54	Publishing web-based guidelines using interactive decision models. Journal of Evaluation in Clinical Practice, 2001, 7, 175-189.	1.8	19

#	Article	IF	Citations
55	Strategies for Treating Latent Multiple-Drug Resistant Tuberculosis: A Decision Analysis. PLoS ONE, 2012, 7, e30194.	2.5	19
56	Systematic review and meta-analysis of endovascular and surgical revascularization for patients with chronic lower extremity venous insufficiency and varicose veins. American Heart Journal, 2018, 196, 131-143.	2.7	17
57	Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation. Annals of Internal Medicine, 2018, 169, 774.	3.9	17
58	Decision science and cervical cancer. Cancer, 2003, 98, 2003-2008.	4.1	15
59	Incidence and predictors of appropriate therapies delivered by the implantable cardioverter defibrillator in patients with ischemic cardiomyopathy: A systematic review. International Journal of Cardiology, 2014, 177, 990-994.	1.7	14
60	Cost-Effectiveness of the Implantable Cardioverter Defibrillator. Journal of Interventional Cardiac Electrophysiology, 2003, 7, 479-482.	1.0	13
61	Do Physiciansâ€™ Attitudes toward Implantable Cardioverter Defibrillator Therapy Vary by Patient Age, Gender, or Race?. , 2011, 16, 77-84.		13
62	Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: Does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. Heart Rhythm, 2013, 10, 828-835.	0.7	13
63	Rheumatologistsâ€™ knowledge of contraception, teratogens, and pregnancy risks. Obstetric Medicine, 2018, 11, 182-185.	1.1	13
64	Future research prioritization in cardiac resynchronization therapy. American Heart Journal, 2020, 223, 48-58.	2.7	13
65	Performance measures to promote quality improvement in sudden cardiac arrest prevention and treatment. American Heart Journal, 2013, 165, 862-868.	2.7	11
66	Future Research Prioritization: Implantable Cardioverter-Defibrillator Therapy in Older Patients. Journal of General Internal Medicine, 2015, 30, 1812-1820.	2.6	11
67	When Is It Safe Not to Reimplant an Implantable Cardioverter Defibrillator at the Time of Battery Depletion?. Cardiac Electrophysiology Clinics, 2018, 10, 137-144.	1.7	11
68	Assessing heterogeneity of treatment effect analyses in health-related cluster randomized trials: A systematic review. PLoS ONE, 2019, 14, e0219894.	2.5	10
69	Optimal Timing of Implantable Cardioverterâ€Defibrillator Implantation After Myocardial Infarction: A Decision Analysis. Journal of Cardiovascular Electrophysiology, 2010, 21, 791-798.	1.7	7
70	Priorities for Comparative Effectiveness Reviews in Cardiovascular Disease. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 139-147.	2.2	7
71	Evidence gaps in economic analyses of hearing healthcare: A systematic review. EClinicalMedicine, 2021, 35, 100872.	7.1	7
72	Assessment of the quality of existing patient educational tools focused on sudden cardiac arrest: a systematic evaluation by the Sudden Cardiac Arrest Thought Leadership Alliance. Patient Preference and Adherence, 2013, 7, 361.	1.8	6

#	Article	IF	Citations
73	Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator?. International Journal of Cardiology, 2014, 172, 253-254.	1.7	4
74	How well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research?. American Heart Journal, 2018, 196, 163-169.	2.7	4
75	Right ventricular lead location and outcomes among patients with cardiac resynchronization therapy: A meta-analysis. Progress in Cardiovascular Diseases, 2021, 66, 53-60.	3.1	2
76	Response to Letter Regarding Article, â€œComparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Womenâ€• Circulation: Heart Failure, 2016, 9, .	3.9	0
77	Do Implantable Cardioverter-Defibrillators Lower the Risk of Sudden Death and Total Mortality in Patients with End-Stage Renal Disease?. Current Cardiovascular Risk Reports, 2017, 11, 1.	2.0	0
78	Implantable Cardioverter Defibrillators for Nonischemic Cardiomyopathyâ€”Reply. JAMA Cardiology, 2017, 2, 1283.	6.1	0
79	Training cardiovascular outcomes researchers: A survey of mentees and mentors to identify critical training gaps and needs. American Heart Journal, 2018, 196, 170-177.	2.7	0
80	Abstract 9509: Is Left Ventricular Lead Placement at Site of Latest Mechanical Activation Associated with Cardiac Resynchronization Therapy Outcomes? Results of a Meta-Analysis. Circulation, 2021, 144, .	1.6	0